• 17

• Nov
• 2022

合作夥伴新聞

VISEN Discloses 52-week Clinical Results for Its China Phase 3 Trial of Lonapegsomatropin Currently

• 07

• Nov
• 2022

合作夥伴新聞

News Release FDA Accepts for Priority Review Ascendis Pharma’s NDA for TransCon™ PTH in Adult Patients with Hypoparathyroidism

• 01

• Aug
• 2022

新聞稿

2022亞洲生技大會登場，台灣維昇分享新創生技藥品公司歷程

• 13

• Mar
• 2022

合作夥伴新聞

Ascendis Pharma A/S Announces Phase 3 PaTHway Trial of TransCon™ PTH in Adults with Hypoparathyroidism Met Primary and All Key Secondary Endpoints

• 13

• Jan
• 2022

合作夥伴新聞

Ascendis Pharma A/S Receives European Approval for TransCon™ hGH for Pediatric Growth Hormone Deficiency

• 28

• Dec
• 2021

新聞稿

專注內分泌創新藥開發 維昇藥業正式在台成立

• 26

• Aug
• 2021

合作夥伴新聞

Ascendis Pharma A/S Announces U.S. Food and Drug Administration Approval of SKYTROFA® (lonapegsomatropin-tcgd), the First Once-weekly Treatment for Pediatric Growth Hormone Deficiency